• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[进展期胃癌第12组淋巴结清扫的临床意义]

[Clinical significance of No.12 lymph node dissection for advanced gastric cancer].

作者信息

You Xiaolan, Wang Yuanjie, Li Wenqi, Zhao Xiaojun, Cheng Zhiyi, Xu Ning, Huang Chuanjiang, Liu Guiyuan

机构信息

Department of Gastrointestinal Surgery, Taizhou People's Hospital, Jiangsu Taizhou 225300, China.

出版信息

Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Mar 25;20(3):283-288.

PMID:28338161
Abstract

OBJECTIVE

To evaluate the clinical significance of No.12 lymph node dissection for advanced gastric cancer with D2 lymphadenectomy.

METHODS

Clinicopathologic data and No.12 lymph node dissection of 256 advanced gastric cancer patients undergoing radical operation in our department between January 2005 and December 2010 were retrospectively summarized and the influence factors of metastasis in No.12 lymph nodes were analyzed.

RESULTS

Of 256 patients, 179 were male and 77 were female with the average age of 59.2 years. Tumor located in the upper of stomach in 24 cases, middle of stomach in 41 cases, lower of stomach in 174 cases, multi-focus or diffuse distribution of stomach in 17 cases. Tumor diameter was <3 cm in 39 cases, 3 to 5 cm in 100 cases, >5 cm in 117 cases. Serum carcinoembryonic antigen (CEA) level increased in 61 cases, serum carbohydrate antigens (CA)72-4 increased in 56 cases and CA19-9 increased in 61 cases. The number of No.12 lymph nodes resected from all the patients was 1 152, and the average number was 4.5±1.9. The metastasis rate of No.12 lymph nodes was 9.4%(24/256) after hematoxylin eosin staining (positive group). All the patients received effective follow-up to December 2015, and the average follow-up time was 101.2 months. The median survival time of positive No.12 group (24 cases) was 29.8 months and of negative No.12 group (232 cases) was 78.2 months, whose difference was statistically significant (χ=21.715, P=0.000). Univariate analysis found that No.12 lymph node metastasis was not associated with age, gender, tumor differentiation (all P>0.05), but was associated with tumor location, tumor diameter, invasive depth (all P<0.05), and was closely associated with Borrmann type, outside metastatic lymph nodes of No.12 and high levels of serum CEA, CA72-4 and CA19-9 (all P=0.000). Multivariate regression analysis found that tumor location (RR=2.452, 95%CI:1.537 to 3.267, P=0.000), Borrmann type (RR=1.864, 95%CI:1.121 to 3.099, P=0.016) and number of outside metastatic lymph nodes of No.12 (RR=2.979, 95%CI: 2.463 to 3.603, P=0.000) were the independent risk factors of the No.12 metastasis (P<0.05).

CONCLUSIONS

Metastasis in No.12 lymph nodes indicates poorer prognosis. The No.12 lymph nodes of advanced gastric cancer patients with curative resection, especially those with the tumor located in the lower part, Borrmann type IIII(, outside metastatic lymph nodes of No.12, should be regularly cleaned.

摘要

目的

评估进展期胃癌行D2淋巴结清扫时第12组淋巴结清扫的临床意义。

方法

回顾性总结2005年1月至2010年12月在我科接受根治性手术的256例进展期胃癌患者的临床病理资料及第12组淋巴结清扫情况,并分析第12组淋巴结转移的影响因素。

结果

256例患者中,男179例,女77例,平均年龄59.2岁。肿瘤位于胃上部24例,胃中部41例,胃下部174例,胃多灶或弥漫分布17例。肿瘤直径<3 cm 39例,3~5 cm 100例,>5 cm 117例。血清癌胚抗原(CEA)升高61例,血清糖类抗原(CA)72-4升高56例,CA19-9升高61例。所有患者共切除第12组淋巴结1 152枚,平均每例4.5±1.9枚。苏木精-伊红染色后第12组淋巴结转移率为9.4%(24/256)(阳性组)。所有患者均获得有效随访至2015年12月,平均随访时间101.2个月。第12组阳性组(24例)中位生存时间为29.8个月,阴性组(232例)为78.2个月,差异有统计学意义(χ=21.715,P=0.000)。单因素分析发现第12组淋巴结转移与年龄、性别、肿瘤分化无关(均P>0.05),但与肿瘤部位、肿瘤直径、浸润深度有关(均P<0.05),且与Borrmann分型、第12组以外转移淋巴结及血清CEA、CA72-4、CA19-9高水平密切相关(均P=0.000)。多因素回归分析发现肿瘤部位(RR=2.452,95%CI:1.537~3.267,P=0.000)、Borrmann分型(RR=1.864,95%CI:1.121~3.099,P=0.016)及第12组以外转移淋巴结数量(RR=2.979,95%CI:2.463~3.603,P=0.000)是第12组转移的独立危险因素(P<0.05)。

结论

第12组淋巴结转移提示预后较差。对行根治性切除的进展期胃癌患者,尤其是肿瘤位于下部、BorrmannⅢ/Ⅳ型、第12组以外有转移淋巴结者,应常规清扫第12组淋巴结。

相似文献

1
[Clinical significance of No.12 lymph node dissection for advanced gastric cancer].[进展期胃癌第12组淋巴结清扫的临床意义]
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Mar 25;20(3):283-288.
2
[Analysis of risk factors and prognosis of No.8p lymph node metastasis in cases with advanced gastric cancer].[进展期胃癌患者8p区淋巴结转移的危险因素及预后分析]
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Feb 25;20(2):218-223.
3
[Prognostic factors of lymph node-negative metastasis gastric cancer].[淋巴结阴性转移性胃癌的预后因素]
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Feb 25;20(2):190-194.
4
[Clinical significance of prognostic nutritional index in patients with advanced gastric cancer].[预后营养指数在进展期胃癌患者中的临床意义]
Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Feb 25;21(2):180-184.
5
[Study on the clinicopathologic characteristics and prognostic difference of gastric stump cancer between non-anastomotic site and anastomotic site].[非吻合口部位与吻合口部位胃残端癌的临床病理特征及预后差异研究]
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Jan 25;20(1):67-72.
6
[Lymph node metastasis regularity and risk factors in 768 cardiac carcinoma patients].768例贲门癌患者淋巴结转移规律及危险因素分析
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Nov 25;20(11):1283-1287.
7
Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.胃癌患者肿瘤标志物的临床评估与预后评价。
Int J Biol Markers. 2013 Jun 28;28(2):192-200. doi: 10.5301/jbm.5000023.
8
[Analysis of clinicopathological characteristics and prognosis on 42 patients with primary gastric adenosquamous cell carcinoma].42例原发性胃腺鳞癌患者的临床病理特征及预后分析
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Feb 25;20(2):207-212.
9
[Metastasis rates of lymph nodes and distribution in advanced gastric cancer and its clinical significance].[进展期胃癌淋巴结转移率及分布情况及其临床意义]
Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):506-9.
10
[Risk factors and prognostic impact of No.12 lymph node metastasis in cases with curable advanced distal gastric cancer].[可治愈的晚期远端胃癌病例中第12组淋巴结转移的危险因素及预后影响]
Zhonghua Yi Xue Za Zhi. 2013 Dec 24;93(48):3847-51.